In a large cohort of RA patients, anti-TNF-α therapy does not increase the risk of serious bacterial infections compared with MTX therapy.110 This leaves the choice of TNFi mainly dependent on practicalities, such as dosing frequency or mode, or on wider economic considerations. This evidence concerns the gene TNF and rheumatoid arthritis.